Phase 2 N=36 Perioperative Chemo and Pembrolizumab in Gastric Cancer
Gastric Cancer · Adenocarcinoma of the Gastroesophageal Junction
Primary: Pathologic Complete Response (pCR) Rate — 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
Cervical Dystonia
Primary: Number of Participants With Treatment-Related Serious Adverse Events — 0; 0; 0; 0 Participants
Phase 2 N=81 PRevention Using EPA Against coloREctal Cancer
Colorectal Adenoma · Colorectal Cancer · Endoscopic Surgery
Primary: Change in the Marine Omega-3 Polyunsaturated Fatty Acid (MO3PUFA) Composition in Colorectal Tissues as a Result of the AMR101 Treatment. — 0.54; 2.95 percentage of total…
Phase 2 N=62 Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Multiple Myeloma · Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Days Post HDT-AHCT Requiring Transfusions or Grade 4 CTCAE Thrombocytopenia — 6 days
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 2 N=3 Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
Carcinoma, Squamous Cell of Head and Neck
Primary: Number of Participants With Response — 0 Participants
Phase 2 N=26 Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
Head And Neck Cancer · Fatigue
Primary: Brief Fatigue Inventory-Worst — 166.8; 154.8 scores on a scale*day
Phase 2 N=62 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 3; 126; 4; 4 Participants
Phase 2 N=462 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Triple Negative Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 5.5; 5.6 Months — p=0.4556
Phase 2 N=141 Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.
Osteoarthritis
Primary: Change From Baseline in Articular Cartilage Collagen Organization in the Overall Cartilage (Femoral and Patellar Lesions) - Part A — 3.02; 2.86; 5.59; 2.05 ms
Phase 2 N=69 Safety and Efficacy of TOP1630 for Dry Eye Syndrome
Dry Eye Syndrome
Primary: Visual Acuity — 0.05; -0.09; 0.017; 0.075 logMAR
Phase 2 N=228 Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
Cannabis Use Disorder
Primary: Time Line Follow Back (TLFB) for Cannabis Use — 1.921; 1.768; 1.201; 1.066 times/day of self-reported cannabis use
Phase 2 N=17 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Phase 2 N=92 Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Gastroparesis · Dyspepsia
Primary: Gastric Emptying Half-time (T1/2) of Solids — 128.7; 125.8; 246.4; 198.4 minutes
Phase 2 N=22 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
Hypothalamic Injury-induced Obesity (HIO)
Primary: Number of Participants With Treatment Emergent Adverse Events — 12; 7 Participants